Tech Company Financing Transactions

Synthekine Funding Round

Deerfield Capital, Janus Henderson Investors and Canaan Partners participated in a $107.5 million Series B funding round for Synthekine. The round closed on 6/11/2021.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1505 O'Brien Dr.
Menlo Park, CA 94025
USA

Phone

(650) 271-9888

Website

www.synthekine.com

Email Address

Not Recorded

Overview

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific, selective and potent cytokine therapies. Our targeted protein engineering guided by our deep experience in immunology provides transformative immunotherapies for the treatment of cancer and autoimmune disorders.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Debanjan Ray

        

Chief Medical Officer

Naiyer Rizvi

        

Vice President

Richard Murphy

        

Vice President

Gregory Yedinak

        

VP - Bus. Development

Martin Oft

        

VP - Finance

Robin Knifsend

        

VP - Operations

Christine Rocha

        

VP - R & D

Robert Kastelein

        

VP - R & D

Patrick Lupardus

        

Browse more venture capital transactions:

Prev: 6/11/2021: Sentera venture capital transaction
Next: 6/11/2021: ViaCyte venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary